O	0	11	Artemisinin	Artemisinin	NN	B-NP
O	12	20	inhibits	inhibit	VBZ	B-VP
B-Cancer	21	26	tumor	tumor	NN	B-NP
O	27	44	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	45	47	by	by	IN	B-PP
O	48	59	suppression	suppression	NN	B-NP
O	60	62	of	of	IN	B-PP
O	63	71	vascular	vascular	JJ	B-NP
O	72	83	endothelial	endothelial	JJ	I-NP
O	84	90	growth	growth	NN	I-NP
O	91	97	factor	factor	NN	I-NP
O	98	99	C	C	NN	I-NP
O	99	100	.	.	.	O

O	102	104	We	We	PRP	B-NP
O	105	109	have	have	VBP	B-VP
O	110	120	previously	previously	RB	I-VP
O	121	129	reported	report	VBN	I-VP
O	130	134	that	that	IN	B-SBAR
O	135	153	dihydroartemisinin	dihydroartemisinin	NN	B-NP
O	154	156	is	be	VBZ	B-VP
O	157	162	found	find	VBN	I-VP
O	163	165	to	to	TO	I-VP
O	166	170	have	have	VB	I-VP
O	171	172	a	a	DT	B-NP
O	173	179	potent	potent	JJ	I-NP
O	180	187	ability	ability	NN	I-NP
O	188	190	in	in	IN	B-PP
O	191	202	influencing	influence	VBG	B-VP
B-Cell	203	212	lymphatic	lymphatic	JJ	B-NP
I-Cell	213	224	endothelial	endothelial	JJ	I-NP
I-Cell	225	229	cell	cell	NN	I-NP
O	230	239	migration	migration	NN	I-NP
O	240	243	and	and	CC	O
B-Tissue	244	248	tube	tube	NN	B-NP
O	249	258	formation	formation	NN	I-NP
O	258	259	.	.	.	O

O	260	262	In	In	IN	B-PP
O	263	267	this	this	DT	B-NP
O	268	273	study	study	NN	I-NP
O	273	274	,	,	,	O
O	275	277	we	we	PRP	B-NP
O	278	290	investigated	investigate	VBD	B-VP
O	291	294	the	the	DT	B-NP
O	295	301	effect	effect	NN	I-NP
O	302	304	of	of	IN	B-PP
O	305	316	artemisinin	artemisinin	NN	B-NP
O	317	319	on	on	IN	B-PP
B-Cancer	320	325	tumor	tumor	NN	B-NP
O	326	332	growth	growth	NN	I-NP
O	332	333	,	,	,	O
O	334	351	lymphangiogenesis	lymphangiogenesis	NN	B-NP
O	351	352	,	,	,	O
O	353	363	metastasis	metastasis	NN	B-NP
O	364	367	and	and	CC	I-NP
O	368	376	survival	survival	NN	I-NP
O	377	379	in	in	IN	B-PP
O	380	385	mouse	mouse	NN	B-NP
B-Cancer	386	391	Lewis	Lewis	NNP	I-NP
I-Cancer	392	396	lung	lung	NN	I-NP
I-Cancer	397	406	carcinoma	carcinoma	NN	I-NP
O	407	408	(	(	(	O
B-Cancer	408	411	LLC	LLC	NN	B-NP
O	411	412	)	)	)	O
O	413	419	models	model	NNS	B-NP
O	419	420	.	.	.	O

O	421	423	We	We	PRP	B-NP
O	424	429	found	find	VBD	B-VP
O	430	434	that	that	IN	B-SBAR
B-Organism_subdivision	435	441	orally	orally	RB	B-NP
O	442	454	administered	administer	VBN	I-NP
O	455	466	artemisinin	artemisinin	NN	I-NP
O	467	476	inhibited	inhibit	VBD	B-VP
B-Multi-tissue_structure	477	482	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	483	487	node	node	NN	I-NP
O	488	491	and	and	CC	O
B-Organ	492	496	lung	lung	NN	B-NP
O	497	507	metastasis	metastasis	NN	I-NP
O	508	511	and	and	CC	O
O	512	521	prolonged	prolonged	JJ	B-NP
O	522	530	survival	survival	NN	I-NP
O	531	538	without	without	IN	B-PP
O	539	548	retarding	retard	VBG	B-VP
B-Cancer	549	554	tumor	tumor	NN	B-NP
O	555	561	growth	growth	NN	I-NP
O	561	562	.	.	.	O

O	563	573	Consistent	Consistent	JJ	B-ADJP
O	574	578	with	with	IN	B-PP
O	579	582	the	the	DT	B-NP
O	583	591	decrease	decrease	NN	I-NP
O	592	594	in	in	IN	B-PP
B-Multi-tissue_structure	595	600	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	601	605	node	node	NN	I-NP
O	606	616	metastasis	metastasis	NN	I-NP
O	616	617	,	,	,	O
B-Cancer	618	623	tumor	tumor	NN	B-NP
O	624	641	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	642	645	and	and	CC	O
O	646	656	expression	expression	NN	B-NP
O	657	659	of	of	IN	B-PP
O	660	668	vascular	vascular	JJ	B-NP
O	669	680	endothelial	endothelial	JJ	I-NP
O	681	687	growth	growth	NN	I-NP
O	688	694	factor	factor	NN	I-NP
O	695	696	C	C	NN	I-NP
O	697	698	(	(	(	O
O	698	702	VEGF	VEGF	NN	B-NP
O	702	703	-	-	HYPH	B-NP
O	703	704	C	C	NN	I-NP
O	704	705	)	)	)	O
O	706	709	was	be	VBD	B-VP
O	710	723	significantly	significantly	RB	I-VP
O	724	733	decreased	decrease	VBN	I-VP
O	734	736	in	in	IN	B-PP
O	737	748	artemisinin	artemisinin	NN	B-NP
O	748	749	-	-	HYPH	B-NP
O	749	756	treated	treat	VBN	I-NP
O	757	761	mice	mouse	NNS	I-NP
O	761	762	,	,	,	O
O	763	765	as	as	IN	B-SBAR
O	766	774	compared	compare	VBN	B-VP
O	775	777	to	to	TO	B-PP
O	778	785	control	control	NN	B-NP
O	786	790	mice	mouse	NNS	I-NP
O	790	791	.	.	.	O

O	792	803	Furthermore	Furthermore	RB	B-ADVP
O	803	804	,	,	,	O
O	805	807	IL	IL	NN	B-NP
O	807	808	-	-	HYPH	B-NP
O	808	813	1beta	1beta	NN	I-NP
O	813	814	-	-	HYPH	B-NP
O	814	821	induced	induce	VBN	I-NP
O	822	825	p38	p38	NN	I-NP
O	826	833	mitogen	mitogen	NN	I-NP
O	833	834	-	-	HYPH	B-VP
O	834	843	activated	activate	VBN	B-NP
O	844	851	protein	protein	NN	I-NP
O	852	858	kinase	kinase	NN	I-NP
O	859	860	(	(	(	O
O	860	864	MAPK	MAPK	NN	B-NP
O	864	865	)	)	)	O
O	866	876	activation	activation	NN	B-NP
O	877	880	and	and	CC	O
O	881	893	upregulation	upregulation	NN	B-NP
O	894	896	of	of	IN	B-PP
O	897	901	VEGF	VEGF	NN	B-NP
O	901	902	-	-	HYPH	B-NP
O	902	903	C	C	NN	I-NP
O	904	908	mRNA	mRNA	NN	I-NP
O	909	912	and	and	CC	I-NP
O	913	920	protein	protein	NN	I-NP
O	921	923	in	in	IN	B-PP
B-Cell	924	927	LLC	LLC	NN	B-NP
I-Cell	928	933	cells	cell	NNS	I-NP
O	934	937	was	be	VBD	B-VP
O	938	942	also	also	RB	I-VP
O	943	953	suppressed	suppress	VBN	I-VP
O	954	956	by	by	IN	B-PP
O	957	968	artemisinin	artemisinin	NN	B-NP
O	969	971	or	or	CC	B-PP
O	972	974	by	by	IN	B-PP
O	975	978	the	the	DT	B-NP
O	979	982	p38	p38	NN	I-NP
O	983	987	MAPK	MAPK	NN	I-NP
O	988	997	inhibitor	inhibitor	NN	I-NP
O	998	1000	SB	SB	NN	I-NP
O	1000	1001	-	-	HYPH	B-NP
O	1001	1007	203580	203580	CD	I-NP
O	1007	1008	,	,	,	O
O	1009	1019	suggesting	suggest	VBG	B-VP
O	1020	1024	that	that	IN	B-SBAR
O	1025	1028	p38	p38	NN	B-NP
O	1029	1033	MAPK	MAPK	NN	I-NP
O	1034	1039	could	could	MD	B-VP
O	1040	1045	serve	serve	VB	I-VP
O	1046	1048	as	as	IN	B-PP
O	1049	1050	a	a	DT	B-NP
O	1051	1059	mediator	mediator	NN	I-NP
O	1060	1062	of	of	IN	B-PP
O	1063	1078	proinflammatory	proinflammatory	JJ	B-NP
O	1079	1087	cytokine	cytokine	NN	I-NP
O	1087	1088	-	-	HYPH	B-VP
O	1088	1095	induced	induce	VBN	B-NP
O	1096	1100	VEGF	VEGF	NN	I-NP
O	1100	1101	-	-	HYPH	B-NP
O	1101	1102	C	C	NN	I-NP
O	1103	1113	expression	expression	NN	I-NP
O	1113	1114	.	.	.	O

O	1115	1120	These	These	DT	B-NP
O	1121	1125	data	datum	NNS	I-NP
O	1126	1134	indicate	indicate	VBP	B-VP
O	1135	1139	that	that	IN	B-SBAR
O	1140	1151	artemisinin	artemisinin	NN	B-NP
O	1152	1155	may	may	MD	B-VP
O	1156	1158	be	be	VB	I-VP
O	1159	1165	useful	useful	JJ	B-ADJP
O	1166	1169	for	for	IN	B-PP
O	1170	1173	the	the	DT	B-NP
O	1174	1184	prevention	prevention	NN	I-NP
O	1185	1187	of	of	IN	B-PP
B-Multi-tissue_structure	1188	1193	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	1194	1198	node	node	NN	I-NP
O	1199	1209	metastasis	metastasis	NN	I-NP
O	1210	1212	by	by	IN	B-PP
O	1213	1227	downregulating	downregulate	VBG	B-VP
O	1228	1232	VEGF	VEGF	NN	B-NP
O	1232	1233	-	-	HYPH	B-NP
O	1233	1234	C	C	NN	I-NP
O	1235	1238	and	and	CC	O
O	1239	1247	reducing	reduce	VBG	B-VP
B-Cancer	1248	1253	tumor	tumor	NN	B-NP
O	1254	1271	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	1271	1272	.	.	.	O

